ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

SYMLIN
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

SYMLIN Rx

Generic Name and Formulations:
Pramlintide (as acetate) 1000mcg/mL; soln for SC inj; contains m-cresol, mannitol.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for SYMLIN:

Type 1 diabetes as adjunct to mealtime insulin, or type 2 diabetes as adjunct to mealtime insulin with or without sulfonylurea and/or metformin, in patients without optimal blood glucose control despite optimal insulin therapy.

Adult:

Do not mix with insulin. Reduce preprandial, short/rapid-acting insulin dose by 50% when starting pramlintide. Adjust insulin dose after target pramlintide dose is achieved and any nausea subsides. Give by SC inj into abdomen or thigh immediately before major meals (≥250 kcal or ≥30g carbohydrates); rotate inj sites (use different site for insulin). Type 1: initially 15mcg; titrate in 15mcg increments if no significant nausea occurs for at least 3 days; maintenance: 60mcg (30mcg only if 60mcg is not tolerated). If nausea occurs at 45 or 60mcg dose, reduce to 30mcg; if not tolerated, consider discontinuing therapy. Type 2: initially 60mcg; may increase to 120mcg if no significant nausea occurs for 3–7days; if nausea occurs at 120mcg reduce to 60mcg.

Children:

Not established.

Contraindications:

Gastroparesis. Hypoglycemia unawareness.

Warnings/Precautions:

Do not use in patients with poor compliance, HbA1c >9%, recurrent hypoglycemia needing assistance in the past 6 months, or if on prokinetic drugs. Monitor blood glucose frequently (pre- and post-meals, and at bedtime). Visual or dexterity impairment. ESRD. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Drugs that alter GI motility (eg, anticholinergics) and those that slow intestinal absorption (eg, α-glucosidase inhibitors): not recommended. May delay absorption of oral drugs (give these 1 hr before or 2 hrs after pramlintide). Increased risk of hypoglycemia with other antidiabetics (eg, sulfonylurea), ACEIs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics; caution.

Pharmacological Class:

Amylin analogue/amylinomimetic.

Adverse Reactions:

Nausea, vomiting, anorexia, headache, allergy; insulin-dependent hypoglycemia (may be severe, esp. in type 1 diabetes).

How Supplied:

SymlinPen 60, 120—2 (pre-filled inj device)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs